A phase 1 clinical trial of BBM-P002 gene therapy has achieved a remarkable safety milestone, with all 12 enrolled patients maintaining good safety profiles and sustaining motor improvements 12 months post-treatment. This 100% safety achievement represents a critical validation for invasive brain-targeted therapies in Parkinson’s disease management.
The trial, published in Nature Medicine, demonstrated no serious adverse events related to the gene therapy despite the surgical delivery of dual adeno-associated virus vectors to the putamen. Participants showed measurable motor function improvements across multiple standardized assessment scales, suggesting that the dual-enzyme approach successfully restored dopamine production capacity in affected brain regions.
These compelling safety and efficacy data provide a strong foundation for advancing BBM-P002 into later-phase clinical trials and may establish a new standard for gene therapy development in neurodegenerative disorders. Read the full article on GMJ Newsroom.
Was this article helpful?
